Patients suffering from idiopathic pulmonary fibrosis, a serious respiratory disease for which no treatment currently exists, are now placing their hopes in the hands of artificial intelligence. They are eagerly awaiting the market launch of Rentosertib, the most advanced treatment entirely designed using AI. According to its developer, the biotech firm Insilico Medicine, Rentosertib “has demonstrated excellent safety and tolerability” as part of its phase 2 clinical trials.
In the field of healthcare, and particularly in the design of new drugs, the emergence of AI promises to be transformative.“Human biology is extraordinarily complex,” says Fiona Marshall, head of biomedical research at Novartis, in an article written for the World Economic Forum in Davos. “A single program can span years or even decades. We design and test thousands of compounds and feel fortunate if even a few advance to clinical testing..” Research and development of a drug costs on average around $2 billion, and the…
